and have used alternative temozolomide dosing schedules and O 6-guanine mimetic agents as substrates for MGMT. In addition, recent studies have attempted to define mechanisms responsible for the ...

Among 165 patients with methylated O 6-methylguanine–DNA methyltransferase (MGMT) status, the median overall survival was 13.5 months with radiotherapy plus temozolomide and 7.7 months with ...

If you have enough tissue, it is beneficial to the patient to check for MGMT because if the patient is methylated, they respond better to chemotherapy such as temozolomide. In our study ...

Ongoing phase III trials in low-grade glioma seek to determine the role of temozolomide in management of these tumors. The first trial, European Organization for Research and Treatment of Cancer ...

Similar to most of the chemotherapy drugs, temozolomide induces DNA damage in cancer cells. Gliomas can progress by repairing this damage through an enzyme encoded by the MGMT gene. In patients ...

Veliparib addition to temozolomide did not significantly extend overall survival in MGMT-hypermethylated glioblastoma patients. The investigational combination was well tolerated, with no significant ...

Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with temozolomide and radiotherapy within its marketing authorisation for newly diagnosed MGMT-methylated glioblastoma ...

“The paper revealed a critical role of GBP3 involving multiple [temozolomide] resistance mechanisms.” “The acquired resistance to the standard adjutant radiochemotherapy including ...

VAL-083 could be the answer to this unmet need for GBM therapy because it is an alkylating agent with a unique mechanism of action. Most agents in this class, such as temozolomide (Temodar ...

Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with temozolomide and radiotherapy within its marketing authorisation for newly diagnosed MGMT-methylated glioblastoma ...